

Violeta Serra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/775286/publications.pdf>

Version: 2024-02-01

93
papers

12,089
citations

50276

46
h-index

38395

95
g-index

104
all docs

104
docs citations

104
times ranked

20630
citing authors

#	ARTICLE	IF	CITATIONS
1	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. <i>Cancer Cell</i> , 2011, 19, 58-71.	16.8	867
2	NVP-BE2235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. <i>Cancer Research</i> , 2008, 68, 8022-8030.	0.9	726
3	Development of PI3K inhibitors: lessons learned from early clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 143-153.	27.6	694
4	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	28.4	527
5	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2016, 76, 2301-2313.	0.9	509
6	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. <i>Cancer Discovery</i> , 2012, 2, 1036-1047.	9.4	507
7	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BE2235. <i>Cancer Research</i> , 2008, 68, 9221-9230.	0.9	474
8	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. <i>Oncogene</i> , 2011, 30, 2547-2557.	5.9	471
9	A decade of clinical development of PARP inhibitors in perspective. <i>Annals of Oncology</i> , 2019, 30, 1437-1447.	1.2	437
10	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016, 167, 260-274.e22.	28.9	376
11	Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1021-1031.	4.1	375
12	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3761-3766.	7.1	291
13	Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. <i>Nature Cell Biology</i> , 2018, 20, 954-965.	10.3	291
14	Short Telomeres in Patients with Vascular Dementia: An Indicator of Low Antioxidative Capacity and a Possible Risk Factor?. <i>Laboratory Investigation</i> , 2000, 80, 1739-1747.	3.7	290
15	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. <i>Annals of Oncology</i> , 2018, 29, 1203-1210.	1.2	280
16	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. <i>Science Translational Medicine</i> , 2015, 7, 283ra51.	12.4	276
17	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 α Inhibitors in PIK3CA-Mutant Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 196ra99.	12.4	251
18	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1606-1622.	1.2	238

#	ARTICLE	IF	CITATIONS
19	Extracellular Superoxide Dismutase Is a Major Antioxidant in Human Fibroblasts and Slows Telomere Shortening. <i>Journal of Biological Chemistry</i> , 2003, 278, 6824-6830.	3.4	229
20	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381.	6.4	215
21	The BRCA1- \hat{p} 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.9	208
22	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. <i>Nature Medicine</i> , 2016, 22, 1303-1313.	30.7	188
23	A $\langle scp \rangle$ RAD $\langle /scp \rangle$ 51 assay feasible in routine tumor samples calls $\langle scp \rangle$ PARP $\langle /scp \rangle$ inhibitor response beyond $\langle scp \rangle$ BRCA $\langle /scp \rangle$ mutation. <i>EMBO Molecular Medicine</i> , 2018, 10, .	6.9	169
24	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 2603-2612.	7.0	154
25	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. <i>Nature</i> , 2017, 547, 109-113.	27.8	142
26	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2257-2269.	1.6	135
27	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. <i>Nature Genetics</i> , 2021, 53, 86-99.	21.4	118
28	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. <i>Annals of Oncology</i> , 2021, 32, 240-249.	1.2	115
29	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2551-2563.	8.2	108
30	BRCA1 Δ 185 tumors may acquire therapy resistance through expression of RING-less BRCA1. <i>Journal of Clinical Investigation</i> , 2016, 126, 2903-2918.	8.2	105
31	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. <i>Oncogene</i> , 2006, 25, 1743-1752.	5.9	102
32	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. <i>Nature Cell Biology</i> , 2018, 20, 211-221.	10.3	98
33	Telomere Length As a Marker of Oxidative Stress in Primary Human Fibroblast Cultures. <i>Annals of the New York Academy of Sciences</i> , 2000, 908, 327-330.	3.8	87
34	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. <i>Journal of Clinical Investigation</i> , 2018, 128, 3887-3905.	8.2	79
35	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , 2021, 11, 2812-2827.	9.4	78
36	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. <i>European Urology</i> , 2021, 79, 200-211.	1.9	76

#	ARTICLE	IF	CITATIONS
37	Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068. <i>Clinical Cancer Research</i> , 2013, 19, 6976-6986.	7.0	72
38	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. <i>Clinical Cancer Research</i> , 2015, 21, 569-576.	7.0	71
39	Targeting p38 $\hat{\pm}$ Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. <i>Cancer Cell</i> , 2018, 33, 1094-1110.e8.	16.8	70
40	Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. <i>Oncogene</i> , 2005, 24, 7542-7551.	5.9	69
41	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. <i>Cancer Discovery</i> , 2022, 12, 356-371.	9.4	68
42	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. <i>Stem Cell Reports</i> , 2017, 8, 1392-1407.	4.8	62
43	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	5.0	60
44	p95HER2 $\hat{\text{e}}$ T cell bispecific antibody for breast cancer treatment. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	59
45	Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. <i>Annals of Oncology</i> , 2021, 32, 1590-1596.	1.2	55
46	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. <i>Translational Oncology</i> , 2020, 13, 410-422.	3.7	52
47	Accelerated telomere shortening in Fanconi anemia fibroblasts - a longitudinal study. <i>FEBS Letters</i> , 2001, 506, 22-26.	2.8	51
48	Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 817-824.	4.1	50
49	Modulation of telomere protection by the PI3K/AKT pathway. <i>Nature Communications</i> , 2017, 8, 1278.	12.8	47
50	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. <i>ESMO Open</i> , 2019, 4, e000480.	4.5	47
51	Stratification and therapeutic potential of PML in metastatic breast cancer. <i>Nature Communications</i> , 2016, 7, 12595.	12.8	45
52	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. <i>Nature Communications</i> , 2018, 9, 3501.	12.8	45
53	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	12.8	45
54	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	9.4	43

#	ARTICLE	IF	CITATIONS
55	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i> -Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	1.6	43
56	Gain- and Loss-of-Function Mutations in the Breast Cancer Gene <i>GATA3</i> Result in Differential Drug Sensitivity. <i>PLoS Genetics</i> , 2016, 12, e1006279.	3.5	43
57	Loss of <i>USP28</i> -mediated <i>BRAF</i> degradation drives resistance to <i>RAF</i> cancer therapies. <i>Journal of Experimental Medicine</i> , 2018, 215, 1913-1928.	8.5	41
58	<i>SLFN11</i> informs on standard of care and novel treatments in a wide range of cancer models. <i>British Journal of Cancer</i> , 2021, 124, 951-962.	6.4	40
59	Preclinical <i>In Vivo</i> Validation of the <i>RAD51</i> Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.9	40
60	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <i>PARP</i> inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11217.	6.9	37
61	Mechanisms of Resistance to <i>PI3K</i> Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. <i>Cancers</i> , 2021, 13, 1538.	3.7	37
62	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. <i>Nature Communications</i> , 2021, 12, 1998.	12.8	37
63	Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3'-overhang. <i>Aging Cell</i> , 2004, 3, 103-109.	6.7	36
64	Effect of <i>p53</i> / <i>HER2</i> / <i>611CTF</i> on the Response to Trastuzumab and Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	36
65	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. <i>Annals of Oncology</i> , 2017, 28, 1207-1216.	1.2	31
66	Direct <i>CDKN2</i> Modulation of <i>CDK4</i> Alters Target Engagement of <i>CDK4</i> Inhibitor Drugs. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 771-779.	4.1	27
67	Human fibroblasts in vitro senesce with a donor-specific telomere length. <i>FEBS Letters</i> , 2002, 516, 71-74.	2.8	24
68	Coamplification of <i>miR-4728</i> protects <i>HER2</i> -amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	7.1	23
69	Targeting a cell state common to triple-negative breast cancers. <i>Molecular Systems Biology</i> , 2015, 11, 789.	7.2	21
70	Genetic Alterations in the <i>PI3K/AKT</i> Pathway and Baseline <i>AKT</i> Activity Define <i>AKT</i> Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , 2020, 26, 3720-3731.	7.0	21
71	Basal expression of <i>RAD51</i> foci predicts olaparib response in patient-derived ovarian cancer xenografts. <i>British Journal of Cancer</i> , 2022, 126, 120-128.	6.4	21
72	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. <i>Molecular Cancer Research</i> , 2019, 17, 2063-2076.	3.4	20

#	ARTICLE	IF	CITATIONS
73	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5499-5510.	7.0	18
74	Chromosome 12p Amplification in Triple-Negative BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. <i>Cancer Research</i> , 2019, 79, 4258-4270.	0.9	17
75	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. <i>Methods</i> , 2015, 77-78, 25-30.	3.8	16
76	Activity of HSP90 Inhibitor in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. <i>Journal of the National Cancer Institute</i> , 2018, 110, 914-917.	6.3	16
77	Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. <i>Melanoma Research</i> , 2006, 16, 147-155.	1.2	13
78	Antitumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. <i>EMBO Molecular Medicine</i> , 2022, 14, e14501.	6.9	13
79	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 1581-1591.	6.4	12
80	High FGFR1 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 137-149.	7.0	12
81	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	8.2	10
82	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. <i>Cancer Research Communications</i> , 2022, 2, 110-130.	1.7	10
83	Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. <i>Npj Breast Cancer</i> , 2021, 7, 111.	5.2	9
84	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	8.2	7
85	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 2562.	3.7	6
86	Sensitizing HR-proficient cancers to PARP inhibitors. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1299272.	0.7	4
87	Clinical consequences of BRCA2 hypomorphism. <i>Npj Breast Cancer</i> , 2021, 7, 117.	5.2	3
88	Identifying the oncogenic role of USP10 as the regulator of PTEN function in breast cancer. <i>Annals of Oncology</i> , 2018, 29, iii10-iii11.	1.2	2
89	mTOR Inhibition Beyond Rapalogs. , 2016, , 251-275.		1
90	FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh). <i>Annals of Oncology</i> , 2017, 28, v575.	1.2	1

#	ARTICLE	IF	CITATIONS
91	Functional transcriptomics: An experimental basis for understanding the systems biology for cancer cells. <i>Advances in Enzyme Regulation</i> , 2007, 47, 41-62.	2.6	0
92	P6346 Transcatheter aortic valve replacement in patients with previous mitral prostheses. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
93	356 Effect of renin-angiotensin system blockade in long term outcomes following transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2018, 39, .	2.2	0